Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Guttman

Showing results (291-300 of 387) with videos related to

Pageof 39
Sort By:
Experimental Dermatology|May 18, 2021
Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe diseaseJonathan T Sims, Ching-Yun Chang, Richard E Higgs, et al.
The Journal of Allergy and Clinical Immunology|May 3, 2014
Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathologySaakshi Khattri, Avner Shemer, Mariya Rozenblit, et al.
The Journal of Allergy and Clinical Immunology|April 29, 2014
Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune responseNikhil Dhingra, Avner Shemer, Joel Correa da Rosa, et al.
American Journal of Clinical Dermatology|October 21, 2025
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III TrialsTiffany Mayo, Jonathan I Silverberg, April Armstrong, et al.
The Journal of Allergy and Clinical Immunology|August 6, 2015
Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsetsTali Czarnowicki, Hitokazu Esaki, Juana Gonzalez, et al.
The Journal of Allergy and Clinical Immunology|October 4, 2022
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studiesEmma Guttman-Yassky, Jacob P Thyssen, Jonathan I Silverberg, et al.
Allergy|April 10, 2023
Age of onset defines two distinct profiles of atopic dermatitis in adultsPaola Facheris, Joel Correa Da Rosa, Angel D Pagan, et al.
Dermatology and Therapy|June 23, 2025
Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)Emma Guttman-Yassky, Stephan Weidinger, Eric L Simpson, et al.
The British Journal of Dermatology|March 30, 2023
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trialsAndrew Blauvelt, Jacob P Thyssen, Emma Guttman-Yassky, et al.
The Journal of Allergy and Clinical Immunology|June 13, 2025
Transcriptomic profiling of vitiligo patients shows polar immune dysregulation in involved and uninvolved skinPatrick M Brunner, Eden David, Ester Del Duca, et al.
Pageof 39

Showing results (291-300 of 387) with videos related to

Sort By:
Pageof 39
Experimental Dermatology|May 18, 2021
Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe diseaseJonathan T Sims, Ching-Yun Chang, Richard E Higgs, et al.
The Journal of Allergy and Clinical Immunology|May 3, 2014
Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathologySaakshi Khattri, Avner Shemer, Mariya Rozenblit, et al.
The Journal of Allergy and Clinical Immunology|April 29, 2014
Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune responseNikhil Dhingra, Avner Shemer, Joel Correa da Rosa, et al.
American Journal of Clinical Dermatology|October 21, 2025
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III TrialsTiffany Mayo, Jonathan I Silverberg, April Armstrong, et al.
The Journal of Allergy and Clinical Immunology|August 6, 2015
Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsetsTali Czarnowicki, Hitokazu Esaki, Juana Gonzalez, et al.
The Journal of Allergy and Clinical Immunology|October 4, 2022
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studiesEmma Guttman-Yassky, Jacob P Thyssen, Jonathan I Silverberg, et al.
Allergy|April 10, 2023
Age of onset defines two distinct profiles of atopic dermatitis in adultsPaola Facheris, Joel Correa Da Rosa, Angel D Pagan, et al.
Dermatology and Therapy|June 23, 2025
Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)Emma Guttman-Yassky, Stephan Weidinger, Eric L Simpson, et al.
The British Journal of Dermatology|March 30, 2023
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trialsAndrew Blauvelt, Jacob P Thyssen, Emma Guttman-Yassky, et al.
The Journal of Allergy and Clinical Immunology|June 13, 2025
Transcriptomic profiling of vitiligo patients shows polar immune dysregulation in involved and uninvolved skinPatrick M Brunner, Eden David, Ester Del Duca, et al.
Pageof 39